Background: Kratom (Mitragyna speciosa) is an increasingly used, largely unregulated botanical product in the United States, commonly taken for analgesia, mood symptoms, and mitigation of opioid withdrawal. Its primary alkaloids, mitragynine and 7-hydroxymitragynine (7-HMG), exhibit opioid and non-opioid receptor activity that may alter perioperative responses to anesthetic agents, sedatives, and opioids. Despite rising use, perioperative guidance remains limited.
Methods: A focused literature review was conducted using PubMed/MEDLINE, Embase, and Web of Science. Search terms included kratom, mitragynine, 7-HMG, anesthesia, perioperative, sedation, analgesia, respiratory effects, withdrawal, and CYP-mediated drug interactions. Peer-reviewed human studies, case reports, and relevant translational research were included.
Results: Evidence suggests multiple mechanisms by which kratom may impact anesthetic care. Kratom alkaloids act as partial agonists at opioid receptors and may contribute to altered analgesic responsiveness and opioid cross-tolerance. Clinical interaction studies demonstrate modest intestinal CYP3A inhibition, increasing exposure to substrates such as midazolam by approximately 39–50%, potentially augmenting early sedative effects. Respiratory effects appear alkaloid-dependent and bidirectional, with 7-HMG producing opioid-like respiratory depression and mitragynine demonstrating stimulant effects. Chronic use may be associated with withdrawal symptoms and variability in perioperative opioid requirements. Additional concerns include product variability and contamination risks.
Conclusion: Current evidence, largely mechanistic and limited clinical data, suggests kratom may significantly influence anesthetic management through opioid-like effects, drug–drug interactions, and unpredictable respiratory physiology. Targeted preoperative screening, individualized anesthetic planning, multimodal analgesia, and enhanced monitoring are recommended. Prospective perioperative studies are needed to establish evidence-based management strategies.
Methods: A focused literature review was conducted using PubMed/MEDLINE, Embase, and Web of Science. Search terms included kratom, mitragynine, 7-HMG, anesthesia, perioperative, sedation, analgesia, respiratory effects, withdrawal, and CYP-mediated drug interactions. Peer-reviewed human studies, case reports, and relevant translational research were included.
Results: Evidence suggests multiple mechanisms by which kratom may impact anesthetic care. Kratom alkaloids act as partial agonists at opioid receptors and may contribute to altered analgesic responsiveness and opioid cross-tolerance. Clinical interaction studies demonstrate modest intestinal CYP3A inhibition, increasing exposure to substrates such as midazolam by approximately 39–50%, potentially augmenting early sedative effects. Respiratory effects appear alkaloid-dependent and bidirectional, with 7-HMG producing opioid-like respiratory depression and mitragynine demonstrating stimulant effects. Chronic use may be associated with withdrawal symptoms and variability in perioperative opioid requirements. Additional concerns include product variability and contamination risks.
Conclusion: Current evidence, largely mechanistic and limited clinical data, suggests kratom may significantly influence anesthetic management through opioid-like effects, drug–drug interactions, and unpredictable respiratory physiology. Targeted preoperative screening, individualized anesthetic planning, multimodal analgesia, and enhanced monitoring are recommended. Prospective perioperative studies are needed to establish evidence-based management strategies.